Abstracts tagged "safety and skin"

Abstract Number: 1026 • 2016 ACR/ARHP Annual Meeting
Morphea-like Skin Lesions Reported in the Phase 3 Long-Term Odanacatib Fracture Trial and Extension in Postmenopausal Women with Osteoporosis
Kenneth G. Saag¹, Tobie de Villiers², Peter Alexandersen³, Heidi Jacobe⁴, Carrie Kovarik⁵, Victoria P. Werth⁶, Albert Leung⁷, Avani Desai-Merchant⁸, Julie Mattaliano⁸ and Deborah Gurner⁸, ¹Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA, Birmingham, AL, ²Mediclinic Panorama and Department of Obstetrics & Gynecology, University of Stellenbosch, Cape Town, South Africa, Cape Town, South Africa, ³Center for Clinical and Basic Research, Vejle, Denmark, Ballerup, Denmark, ⁴Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, ⁵Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ⁶Philadelphia VAMC, Philadelphia, PA, USA, Philadelphia, PA, ⁷Formerly Merck & Co., Inc., Kenilworth, NJ, USA, Kenilworth, NJ, ⁸Merck & Co., Inc., Kenilworth, NJ, USA, Kenilworth, NJ
Background/Purpose: LOFT was a double-blind, placebo-controlled trial. Women ≥65 years with total hip (TH) or femoral neck (FN) bone mineral density (BMD) T-score ≤-2.5, or…
Abstract Number: 2204 • 2014 ACR/ARHP Annual Meeting
New Onset Vitiligo Under Biological Agents: A Case Series
Laure Mery-Bossard¹, Emmanuelle Mahé², Guillaume Charby³, François Maccari⁴, Nathalie Quilès⁵, Ziad Reguiai⁶, Abdallah Khemis⁷, Anne Grasland⁸, Morgane Guerin⁹, Denis Jullien¹⁰, Kelly Bagny¹¹, Jean Sibilia¹², Eric Toussirot^13,14 and Resopso Le CRI¹⁵, ¹Dermatology, Centre hospitalier, Mantes la Jolie, France, ²Dermatology, Centre hospitalier, Argenteuil, France, ³Dermatology, University hospital, Amiens, France, ⁴Dermatology, Centre hospitalier, Saint Mandé, France, ⁵Dermatology, University hospital, Marseille, France, ⁶Dermatology, Uniersity hospital, Reims, France, ⁷Dermatology, University hospital, Nice, France, ⁸Internal medicine, University hospital, Colombe, France, ⁹Dermatology, University hospital, Lyon, France, ¹⁰Pavillon r dermatologie, Hopital Edouard Herriot, Lyon, France, ¹¹Rheumatology, University hospital, La Réunion, France, ¹²Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ¹³Clinical Investigation Centre Biotheraoy CIC 1431, Rheumatology Department, Univesity Hospital, besancon, France, ¹⁴Rheumatology, University hospital, Besançon, France, ¹⁵University Hospital, Paris, France
Background/Purpose: biological agents are now widely used in clinical practice for the treatment of chronic cutaneous, rheumatic and gastro-intestinal inflammatory diseases. Various cutaneous lesions have…
Abstract Number: 1972 • 2014 ACR/ARHP Annual Meeting
Analysis of Anakinra in Primary Human Cell Systems Reveals an in Vitro Signature for Skin-Related Side Effects
Ellen L. Berg, Alison O'Mahony and Mark A Polokoff, BioSeek, South San Francisco, CA
Background/Purpose The therapeutic options for treatment of rheumatic diseases have grown and now include a variety of inflammatory pathway inhibitors, with diverse mechanisms, but having…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].